Keros Therapeutics, Inc., was originally incorporated under the laws of the State of Delaware in December 2015. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for patients with hematological and musculoskeletal diseases. The company is a leader in understanding the role of transforming growth factor-beta (a family of proteins), a major regulator of red blood cell and platelet production and muscle and bone growth, repair and maintenance. 

Keros Therapeutics Inc. has announced <a href="https://www.google.com/goto?url=CAESgAEB6zswFWjbg8_a93mioDlJYNf3zXsnH0thN-bvDlpUMD4_ozM4gKOaMYL1iPccMlaHLC1qGnpWkClRjS9klZR-PMAWyxbqvegZ2isoFOpmjHF-cMNJJKzZJclnTppBoZQfzWbJ-7ZxXw42V_5DqbR7_Tno8pfpNBHvFi7zZFOqaQ">offering of up to $100 million</a> in common stock under a sales agreement with Leerink Partners LLC, as disclosed in a recent SEC filing. The company has entered into an at-the-market offering agreement, allowing it to sell shares from time to time through Leerink Partners, subject to market conditions and other factors. The offering is intended to provide the company with additional capital to support its operations and strategic initiatives.The terms of the offering, including the number of shares to be issued and the price, remain subject to market demand and other conditions. Investors are advised to <a href="https://www.google.com/goto?url=CAESgAEB6zswFWjbg8_a93mioDlJYNf3zXsnH0thN-bvDlpUMD4_ozM4gKOaMYL1iPccMlaHLC1qGnpWkClRjS9klZR-PMAWyxbqvegZ2isoFOpmjHF-cMNJJKzZJclnTppBoZQfzWbJ-7ZxXw42V_5DqbR7_Tno8pfpNBHvFi7zZFOqaQ">review the full details</a> of the offering in the SEC filing for a comprehensive understanding of the terms and risks involved. The company has not disclosed a specific timeline for the commencement or completion of the offering. As with any securities offering, potential investors should consider the company’s financial position, market risks, and other relevant factors before making investment decisions.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1e17c5594db002.png" alt="Keros Therapeutics - May offer up to $100 mln of common stock under sales agreement with Leerink Partners - SEC filing">

Keros

Keros Therapeutics - May offer up to $100 mln of common stock under sales agreement with Leerink Partners - SEC filing

Keros Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) to <a href="https://www.google.com/goto?url=CAESXQHrOzAVvLQEZ3ad0sH4x_JmOa9rfBKM2FteUQpUpeZXQkzbuXkqizGhQZIwQf07S7GTHBBRTICBI3X5Z508a_ccRqZPPJZz-o3XeoT8lA5VtossPfbAd34fcQ6CSw">offer up to $350 million</a> in securities, according to a recent SEC filing. The offering, which includes common stock, preferred stock, debt securities, and/or warrants, is part of the company’s ongoing capital-raising efforts. The size and structure of the offering suggest a strategic move to strengthen the company’s financial position, potentially supporting ongoing research and development initiatives or other corporate objectives.The terms of the offering, including pricing, number of shares, and use of proceeds, have not yet been finalized and will be determined based on market conditions and investor demand. The company has not disclosed specific details regarding the allocation of funds or the expected timeline for the offering’s completion. As with any securities offering, potential investors are advised to review the full SEC filing for detailed information and to consider the associated risks.The offering remains subject to market conditions and regulatory approvals. Investors should monitor subsequent filings and announcements for updates.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1e17b2358db002.png" alt="Keros Therapeutics - May offer up to $350 mln of securities - SEC filing">

Keros Therapeutics - May offer up to $350 mln of securities - SEC filing

Keros Therapeutics has authorized a $5 million share buyback program after receiving a $20 million milestone payment from Takeda Pharmaceuticals for the dosing of the first patient in the Phase 3 ELRiSE MDS clinical trial. The company's board approved the repurchase of shares periodically through open-market transactions and other permitted methods, subject to market conditions, share price, and other factors. Keros Therapeutics focuses on developing therapeutics linked to dysfunctional signalling of the transforming growth factor-beta family of proteins.

Takeda Pharmaceutical

Keros Therapeutics Authorizes $5 Mln Share Buyback Following Takeda Milestone Payment

Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million development milestone payment for elritercept from Takeda Pharmaceuticals. The program allows management to repurchase outstanding shares in the open market or by other means, subject to various factors and contractual limitations. Keros is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional TGF-ß protein signaling.

Keros Therapeutics Gets $5 Million for Share Repurchase

Keros Therapeutics, Inc. (Nasdaq: KROS) has announced a $5 million share repurchase authorization as part of its broader capital return program. The company has already completed the repurchase of shares held by ADAR1 Capital Management and Pontifax Venture Capital for <a href="https://www.google.com/goto?url=CAESrQEB6zswFSi8ABHBnyZG-cA6Z3c25zagkwafIvag7Z5g5a8PIMyaS2Gtlqatm_pPQmms0z6YmNkqrvefvT2x2ttp91KShNE4G1UQteIBaPL1zAAX6t1DOmWisFLtno2hgPp090YmFYjmoNmDcsrM1AA9iGP-7xkyrFhw640Yhs_0yavB0r2tbn_lKA2pK4WxX3wA-yCdfpQzpcWb2lWVVPRM07p7QjLBgus2w2iNWw">a total of $181 million</a> at $17.75 per share. Following these transactions, Keros commenced <a href="https://www.google.com/goto?url=CAESsgEB6zswFeYW1DlrIBaMyh_0-sRGA7yPjtLWqQ3EV94Hrg9LLgxVXcoOmV3ZG6z0sIrLKwGTZW0QHEYhSP-1ju0Z6w3luQUf6HnZQ83wnOmgwgnQ2mr4GWu-j2MNJjommJULW1GkFX7zeg01MY1JTphLgTLxuieXAu69wp3HHPtOHjJlSPv5tTVFTJ0dKGa_nmdEw6VnekZThCd6ZDLYkwui56BaTBc4tyVbXzy-1pYe0vP1">a tender offer</a> to repurchase up to $194 million of additional shares at the same price. The $5 million authorization appears to be a continuation of this strategy, aimed at returning capital to shareholders while maintaining financial flexibility.The repurchase program is funded from the company’s existing cash and cash equivalents, reflecting Keros’ strong liquidity position. The company has also committed to <a href="https://www.google.com/goto?url=CAESrQEB6zswFSi8ABHBnyZG-cA6Z3c25zagkwafIvag7Z5g5a8PIMyaS2Gtlqatm_pPQmms0z6YmNkqrvefvT2x2ttp91KShNE4G1UQteIBaPL1zAAX6t1DOmWisFLtno2hgPp090YmFYjmoNmDcsrM1AA9iGP-7xkyrFhw640Yhs_0yavB0r2tbn_lKA2pK4WxX3wA-yCdfpQzpcWb2lWVVPRM07p7QjLBgus2w2iNWw">distributing 25% of net cash</a> proceeds from its global license agreement with Takeda Pharmaceuticals U.S.A., Inc. to stockholders, further reinforcing its capital return focus.Keros remains focused on advancing its clinical programs, including KER-065 for Duchenne muscular dystrophy and elritercept for cytopenias. The company continues to <a href="https://www.google.com/goto?url=CAESrQEB6zswFSi8ABHBnyZG-cA6Z3c25zagkwafIvag7Z5g5a8PIMyaS2Gtlqatm_pPQmms0z6YmNkqrvefvT2x2ttp91KShNE4G1UQteIBaPL1zAAX6t1DOmWisFLtno2hgPp090YmFYjmoNmDcsrM1AA9iGP-7xkyrFhw640Yhs_0yavB0r2tbn_lKA2pK4WxX3wA-yCdfpQzpcWb2lWVVPRM07p7QjLBgus2w2iNWw">target a Phase 2 clinical</a> trial start for KER-065 in early 2026. The share repurchase authorization underscores Keros’ confidence in its long-term strategic and financial outlook.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1b83f6508db002.png" alt="Keros Therapeutics announces $5 million share repurchase authorization">

KROS News